IBIO · iBio, Inc.
$1.41
+0.04 (+2.92%)
At close · Jul 21
Going-concern doubt
— cleared May 12, 2026
The latest filing states the doubt was alleviated.
“The history of significant losses, the negative cash flow from operations, and the dependence by the Company on its ability to obtain additional financing to fund its operations in the past raised substantial doubt about the Company's ability to continue as a going concern.”View the 10-Q filed May 12, 2026
Market Cap
$67.81M
Shares
49.68M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
Fiscal 2021
| Executive | Role | Total |
|---|---|---|
| Thomas Isett | CEO | $4,839,712 |
| Randy J Maddux | COO | $1,518,082 |
| DR. MARTIN BRENNER | Chief Executive Officer and Chief Scientific Officer of iBio | $1,014,282 |
Fiscal 2020
| Executive | Role | Total |
|---|---|---|
| Thomas Isett | CEO | $1,763,224 |
| Randy J Maddux | COO | — |
| DR. MARTIN BRENNER | Chief Executive Officer and Chief Scientific Officer of iBio | — |
Fiscal 2019
| Executive | Role | Total |
|---|---|---|
| Robert B. Kay | CEO | $347,604 |
| James P. Mullaney | CFO | $319,167 |
| Robert L. Erwin | President | $275,000 |
| Terence E. Ryan | Chief Scientific Officer | $200,000 |
Fiscal 2018
| Executive | Role | Total |
|---|---|---|
| Robert B. Kay | CEO | $314,899 |
| Robert L. Erwin | President | $251,666 |
| James P. Mullaney | CFO | $240,000 |
| Terence E. Ryan | Chief Scientific Officer | $200,000 |
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Evert Schimmelpennink | member of the Board | Resigned | 2026-05-08 |
| Dr. Elizabeth Stoner, M.D., M.S. | Class II director | Appointed | 2026-05-08 |